APA (7th ed.) Citation

DD, Z., SJ, L., FP, L., WA, C., M, Z., RJ, S., . . . CK, L. (2026). Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials. Lung cancer (Amsterdam, Netherlands), 212, 108891. https://doi.org/10.1016/j.lungcan.2025.108891

Chicago Style (17th ed.) Citation

DD, Zhou, Lord SJ, Lin FP, Cooper WA, Zaheed M, Simes RJ, John T, and Lee CK. "Clinical Impact of TP53 Classifications in Previously Treated Advanced Driver-negative Non-small Cell Lung Cancer: A Biomarker Analysis of the OAK and POPLAR Randomized Clinical Trials." Lung Cancer (Amsterdam, Netherlands) 212 (2026): 108891. https://doi.org/10.1016/j.lungcan.2025.108891.

MLA (9th ed.) Citation

DD, Zhou, et al. "Clinical Impact of TP53 Classifications in Previously Treated Advanced Driver-negative Non-small Cell Lung Cancer: A Biomarker Analysis of the OAK and POPLAR Randomized Clinical Trials." Lung Cancer (Amsterdam, Netherlands), vol. 212, 2026, p. 108891, https://doi.org/10.1016/j.lungcan.2025.108891.